Helus Pharma’s Short-Acting Depression Drug Shows Durable Benefit in Phase 2a Trial

Cybin ( (HELP) ) just unveiled an update.

Helus Pharma reported that Nature Medicine has published results from its randomized, placebo-controlled Phase 2a trial of SPL026 in patients with moderate-to-severe major depressive disorder. The study showed that a single dose of SPL026 led to statistically significant and clinically meaningful reductions in depressive symptoms versus placebo at two weeks, with benefits emerging within one week and in some cases lasting up to six months, and the treatment was generally well tolerated with no serious adverse events.

The findings provide clinical proof-of-concept for short-acting serotonergic agonists as a viable and potentially more cost-effective intervention for depression, supporting Helus Pharma’s broader strategy in this drug class. While the company is not continuing SPL026 in its current intravenous form, the mechanistic and clinical insights are being used to drive development of its next-generation compound HLP004, with Phase 2 topline data in generalized anxiety disorder expected in early 2026, which could strengthen its position in emerging psychiatric therapeutics.

The most recent analyst rating on (HELP) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Cybin stock, see the HELP Stock Forecast page.

More about Cybin

Helus Pharma is a clinical-stage pharmaceutical company focused on developing novel short-acting serotonergic agonists to treat serious mental health conditions such as major depressive disorder and generalized anxiety disorder. The company is advancing proprietary compounds like HLP004, designed for optimized pharmacology, dosing consistency, and scalable commercial use in psychiatric care.

Average Trading Volume: 659,424

Technical Sentiment Signal: Strong Sell

Current Market Cap: $1.41M

See more data about HELP stock on TipRanks’ Stock Analysis page.